Lund, Sweden, September 23, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the following upcoming investor conferences:
Redeye Online Investor Forum
Date: Thursday, September 23, 2021
Time: 15:00-16:40 (CET)
Redeye Malmö Investor Forum
Location: Malmö, Sweden
Date: Thursday, September 30, 2021
Time: 18:00-20:00 (CET)
21st Annual Biotech in Europe Forum
Location: Virtual IO Advanced Therapeutics Panel
Dates: Thursday, October 7 – Friday, October 8, 2021
Time: 13:30 – 14:30pm (CET)
Vator Securities Healthcare Innovation Summit
Date: Thursday, October 7, 2021
Time: 11:40 – 12:00 CEST
BioStock Life Science Summit
Date: Wednesday, October 20, 2021
All presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at Redeye, Vator Securities, and/or BioStock if you wish to attend and/or schedule a meeting with Alligator.
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Outlicensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden.
For more information, please visit http://www.alligatorbioscience.com.